【小剂量阿司匹林可预防狼疮患者…
小剂量阿司匹林可预防狼疮患者的心血管事件发生
作者：Iudici M, et al. 翻译：李常虹发布者：于若寒，校正：刘佩玲
摘要（意大利）目的：红斑狼疮（SLE）患者中心血管疾病（CV）的发病率和死亡率均显著高于普通人群。现已知阿司匹林的使用与心血管疾病高风险普通人群的CV发生率下降有关，但它对于SLE人群发生CV事件初级预防的效果尚不清楚。
方法：连续记录符合1992年ACR和/或2012年SLICC制定的SLE分类标准且未发生过任何CV事件的SLE患者的临床特征。每次随访时记录任何CV事件发生情况。每次随访时均记录阿司匹林停用率和停用原因。
结果：167例SLE患者被纳入本项研究，并平均随访8年。在这些人群中，146例患者规律服用了阿司匹林和21例患者拒绝或中断使用该药物。在146例接受阿司匹林治疗的SLE患者中发生了5件CV事件，而在21例拒绝接受或中断阿司匹林治疗的SLE患者中发生了4件CV事件。阿司匹林治疗组无CV事件的发生率显著高于非阿司匹林干预组。并未发现阿司匹林相关的不良反应。
结论：小剂量阿司匹林是一种安全的治疗方式，作为CV事件的初级预防措施可能对SLE患者有益。仍需要前瞻性对照研究去更好的明确阿司匹林在SLE患者治疗中的地位。
附原文：Abstract OBJECTIVES: Cardiovascular (CV) morbidity and mortality are significantly greater in SLE patients than in the general population. ASA is known to be associated with a decrease in the incidence of CV events in high-risk patients from the general population, but its efficacy as primary prophylaxis in SLE patients has not yet been investigated.METHODS: The clinical charts of SLE patients consecutively admitted to a tertiary centre who, at admission, satisfied 1992 ACR and/or 2012 SLICC classification criteria for SLE and had not experienced any CV event, were reviewed. The occurrence of any CV event was recorded at each visit. ASA was prescribed to all patients at first visit. The rate and reasons for ASA discontinuation were also recorded at each visit.RESULTS: One hundred and sixty-seven consecutive SLE patients were enrolled and followed up for a median of 8 years (range 1-14 years). Among them, 146 regularly took the medication (ASA-treated patients) and 21 refused to take or discontinued it (non-ASA-treated patients). Five CV events occurred in the 146 ASA-treated patients (4.2 per 1000 person-years) and four in the 21 non-ASA-treated patients (30 per 1000 person-years; P = 0.0007). The CV event-free rate was higher in ASA-treated than in non-ASA-treated patients (log-rank test χ2 = 15.74; P = 0.0001). No relevant side-effect related to ASA was recordedCONCLUSION: Low-dose ASA is a safe treatment and may be beneficial in the primary prophylaxis of CV events in SLE patients. Controlled, prospective studies are needed to provide a better definition of its role in these patients.
引自：Iudici M, Fasano S, Gabriele Falcone L, Pantano I, La Montagna G, Migliaresi S, Valentini G.Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016 May 31. pii: kew231. [Epub ahead of print]
作者：Iudici M, et al. 翻译：李常虹
摘要（意大利）目的：红斑狼疮（SLE）患者中心血管疾病（CV）的发病率和死亡率均显著高于普通人群。现已知阿司匹林的使用与心血管疾病高风险普通人群的CV发生率下降有关，但它对于SLE人群发生CV事件初级预防的效果尚不清楚。
方法：连续记录符合1992年ACR和/或2012年SLICC制定的SLE分类标准且未发生过任何CV事件的SLE患者的临床特征。每次随访时记录任何CV事件发生情况。每次随访时均记录阿司匹林停用率和停用原因。
结果：167例SLE患者被纳入本项研究，并平均随访8年。在这些人群中，146例患者规律服用了阿司匹林和21例患者拒绝或中断使用该药物。在146例接受阿司匹林治疗的SLE患者中发生了5件CV事件，而在21例拒绝接受或中断阿司匹林治疗的SLE患者中发生了4件CV事件。阿司匹林治疗组无CV事件的发生率显著高于非阿司匹林干预组。并未发现阿司匹林相关的不良反应。
结论：小剂量阿司匹林是一种安全的治疗方式，作为CV事件的初级预防措施可能对SLE患者有益。仍需要前瞻性对照研究去更好的明确阿司匹林在SLE患者治疗中的地位。
附原文：Abstract OBJECTIVES: Cardiovascular (CV) morbidity and mortality are significantly greater in SLE patients than in the general population. ASA is known to be associated with a decrease in the incidence of CV events in high-risk patients from the general population, but its efficacy as primary prophylaxis in SLE patients has not yet been investigated.METHODS: The clinical charts of SLE patients consecutively admitted to a tertiary centre who, at admission, satisfied 1992 ACR and/or 2012 SLICC classification criteria for SLE and had not experienced any CV event, were reviewed. The occurrence of any CV event was recorded at each visit. ASA was prescribed to all patients at first visit. The rate and reasons for ASA discontinuation were also recorded at each visit.RESULTS: One hundred and sixty-seven consecutive SLE patients were enrolled and followed up for a median of 8 years (range 1-14 years). Among them, 146 regularly took the medication (ASA-treated patients) and 21 refused to take or discontinued it (non-ASA-treated patients). Five CV events occurred in the 146 ASA-treated patients (4.2 per 1000 person-years) and four in the 21 non-ASA-treated patients (30 per 1000 person-years; P = 0.0007). The CV event-free rate was higher in ASA-treated than in non-ASA-treated patients (log-rank test χ2 = 15.74; P = 0.0001). No relevant side-effect related to ASA was recordedCONCLUSION: Low-dose ASA is a safe treatment and may be beneficial in the primary prophylaxis of CV events in SLE patients. Controlled, prospective studies are needed to provide a better definition of its role in these patients.
引自：Iudici M, Fasano S, Gabriele Falcone L, Pantano I, La Montagna G, Migliaresi S, Valentini G.Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016 May 31. pii: kew231. [Epub ahead of print]
收藏
回复(7)举报
参与评论
评论列表
按投票顺序
平静生活我也每天吃一颗
举报
2016-06-15 22:30:39 有用(1)
回复(0)
蓝天、白云我上个月也开始口服1片阿司匹林，可是我胃不太好。
举报
2016-06-17 19:32:17 有用(0)
回复(0)
蓝天、白云我听说这种药对肾和胃不太好
举报
2016-06-17 19:33:38 有用(0)
回复(0)
蓝天、白云有人吃沙度利胺这药吗
举报
2016-06-17 19:36:21 有用(0)
回复(0)
麦芽✊我每天都吃阿司匹林的
举报
2016-06-15 17:35:37 有用(0)
回复(0)
想与美丽结缘^_^吃阿司匹林感觉身上淤青好严重
举报
2016-06-15 17:51:10 有用(0)
回复(0)
小狼女开始吃一颗
举报
2016-06-15 23:54:49 有用(0)
回复(0)
相关推荐
热点推荐
暂无数据
热门帖子
今日推荐
推荐关注
